Chapter category: Endocrine
The Clinical Prospects of the Invincible PTHs
Growing Bone
Second Edition
Edited by: James F. WhitfieldISBN: 978-1-58706-156-1
» Get more information about this book at landesbioscience.com «
Chapter authors:
James F. Whitfield
The osteoporosis market is a rapidly growing “marketer’s” dream. And several years ago there was no known bone-growing drug—only the ever-worrisome (for cancerophobics) estrogens and the other antiresorptives. So the marketeers at Eli Lilly decided that the old hPTH-(1-34) would be the ideal drug with which to break into this pharmaceutical gold mine. All they had to do was take it off the shelf, brush off the dust, spider webs and dead flies, and infect Escherichia coli with a suitable expression vector into which the gene had been stitched to make it, and then sell tons of it to the growing hordes of fracturing “greys” to toughen up their fragile bones and strengthen the anchorage of the artificial hips and knees they will also need.Thus was born Lilly’s recombinant hPTH-(1-34) which was officially approved for clinical use under the trade name Forteo™ by the USFDA in November 2002.
James F. Whitfield
Institute for Biological Sciences
National Research Council of Canada
Ottawa, Ontario, Canada
Additional chapters from this book:
Strontium, Calcium’s Big Brother
James F. Whitfield
Strontium (Sr) has been very recently hyped as the latest “paradigm-changing” thing in the treatmen of osteoporosis as indicated by the title of a paper by Reginster et al (2003)—“Strontium Ranelate: ...
Surface Signaling Steroids—Real Anabolics or Pseudo-Anabolics?
James F. Whitfield
In 1998 Sicinski et al reported the synthesis of new 1a, 25-(OH)2-19-nor-vitamin D3 analogs such as 2MD (2-methylene-19-nor-(20S)-1a,25(OH)2D3) which are super-potent derivatives of the natural 1a, 25...
The Statins
James F. Whitfield
While the PTHs are by far the leading anabolic agents for treating osteoporosis and mending fractures, another family of drugs has been trying to challenge them but with very mixed results (Mundy, 200...
OGP—The Osteogenic Growth Peptide
James F. Whitfield
Scooping out the marrow or driving a nail into the marrow cavity of a bone such as the tibia, like a fracture, causes the marrow cavity to fill with a blood clot and releases a shower of osteogenic si...
The Clinical Prospects of the Invincible PTHs
James F. Whitfield
The osteoporosis market is a rapidly growing “marketer’s” dream. And several years ago there was no known bone-growing drug—only the ever-worrisome (for cancerophobics) estrogens and the other antires...
How Might PTHs Stimulate Bone Growth?
James F. Whitfield
To tackle the formidable job of understanding how the PTHs stimulate bone growth in humans, rodents and other animals (Fig. 17) we must know where and how things start. What signals do they send into...
The Amazing Bone-Anabolic PTHs
James F. Whitfield
Clearly the antiresorptives are far from being the ‘Holy Grails’ of osteoporosis therapy although they do break the vicious cyle of escalating remodeling and microdamage (Fig. 10). Since by the time o...
Menopause and Bone Loss
James F. Whitfield
So far it has seemed that estrogen is the primus inter pares of an ever-growing number of agents that control bone growth and strength in both women and, perhaps surprisingly, men (Baylink et al, 1999...
BMUS—The Microcrack Fixers
James F. Whitfield
At first sight bones are inert, rock-like things that store 99% of the body’s calcium and consist of a hard shell, the cortex, that encloses a deceptively delicate lattice of struts and plates (Jee, 2...
What Is Osteoporosis?
James F. Whitfield
Osteoporotic postmenopausal women don’t need to fall or hit something to break their fragile bones. Their, hips, ribs, wrists and especially vertebrae are apt to be broken or crushed by bending spines...
